Goldman Small Cap Research Publishes New Research Report on Sigyn Therapeutics Inc.

BALTIMORE, MD / ACCESSWIRE / March 4, 2021 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Sigyn Therapeutics Inc. (OTC PINK:SIGY). Sigyn is a development stage therapeutic technology company focused on the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome (CSS) and not addressed with an approved therapy, including sepsis and COVID-19. This report carries a price target. To view the new research report, along with disclosures and disclaimers, or to download it in its entirety, please visit. https://bit.ly/3v1Xi0T.

Sigyn's leverages a novel blood purification technology design and its founders extensive experience in developing therapeutic devices. The Company is advancing this technology through a series of studies and trials, culminating in the filing of an IDE with the FDA later this year. The flagship platform is a candidate to prevent or mitigate Cytokine Storm Syndrome, a life-threatening immune response precipitated by a wide-range of infectious and non-infectious conditions which can lead to multiple organ failure and cause death. The annual market opportunity for a therapeutic strategy to prevent or mitigate the Cytokine Storm is in the tens of billions annually.

In the Opportunity Research report, analyst Rob Goldman discusses how the Company's unique approach and enviable leadership combine to potentially emerge as the go-to therapy to treat life-threatening inflammatory conditions that are precipitated by CSS.

Goldman commented, "In our view, Sigyn is poised to change the way acute, life-threatening inflammatory conditions induced by Cytokine Storm Syndrome are treated. Many of these conditions have no approved therapy and represent billions in market size. The primary targeted conditions include COVID-19 and sepsis, the #1 cause of deaths in hospitals worldwide. We believe the Company's sepsis opportunity is $17B in the US alone."

"Sigyn has reported favorable in vitro results and is poised to file an IDE with the FDA later this year. The Company could be awarded Breakthrough Device designation and Emergency Use Authorizations in the coming quarters which could make Sigyn an attractive M&A target by Tier 1 medical device players," noted Goldman.

"The Company boasts enviable leadership that is second to none in this therapeutic category. The CEO has led NASDAQ-listed device companies and co-authored submissions that resulted in two FDA Breakthrough Device awards. The co-founders oversaw the development of three devices that were approved by the FDA to treat COVID-19."

"Based on Sigyn's its unique approach, and the value of upcoming milestones as Sigyn transitions from a development stage company to a clinical stage firm, we believe that these shares could reach our price target in the next six to twelve. months," concluded Goldman. "Our target is further affirmed by using a discounted potential value of revenue generated as an FDA-approved Breakthrough Device and EUA treatment for sepsis alone."

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.

Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published company report on Sigyn Therapeutics Inc. ("The Company"). The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Sigyn Therapeutics Inc. The information includes authorized press releases or legal disclosures made in their filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets, and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, sector or industry snapshot, podcast interview, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. A Speculative Buy rating for our covered companies is defined as a company that we believe exhibits the potential to generate outsized returns despite inherent, above-average business, market, or financial risk. To download this research report or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was compensated $7500 by the Company for the production and distribution of research reports and associated press releases and distribution.

Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com

SOURCE: Goldman Small Cap Research

Released March 4, 2021